![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Bi-weekly Dosing of ARB-1467 LNP siRNA in HBeAgNegative, Virally Suppressed Patients with Chronic HBV Infection Leads to Deeper Declines in HBsAg and Potential Association with IL28b
|
|
|
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
KoshAgarwal 1, Ed Gane2, Wendy Cheng 3, William Sievert 4, Stuart Roberts 5, Sang HoonAhn6, Yoon Jun Kim 7, Adrian Streinu-Cercel8, Jill Denning 9, William Symonds 9, Patricia Mendez 9
1 King's College Hospital Foundation Trust, United Kingdom; 2Auckland Clinical Studies Limited, Auckland, New Zealand; 3Royal Perth Hospital and Linear Research, Perth, Australia; 4Monash Health and Monash University, Melbourne, Australia; 5The Alfred, Melbourne, Australia; 6Yonsei University College of Medicine, Seoul, South Korea; 7Seoul National University College of Medicine, Seoul, South Korea; 8Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases "Prof. Dr. MateiBals", Bucharest, Romania; 9Arbutus Biopharma Corporation, Burnaby, Canada.
![1108171](../images/110817/110817-20/1108171.gif)
![1108172](../images/110817/110817-20/1108172.gif)
![1108173](../images/110817/110817-20/1108173.gif)
![1108174](../images/110817/110817-20/1108174.gif)
![1108175](../images/110817/110817-20/1108175.gif)
![1108176](../images/110817/110817-20/1108176.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|